Real-world treatment patterns of patients with EGFR exon 20 insertion–mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort study
This retrospective study described patient characteristics, treatment patterns, and outcomes in patients with EGFR exon20ins-mutated advanced or metastatic NSCLC who received amivantamab or mobocertinib monotherapy after platinum-based chemotherapy. Real-world patients treated with amivantamab experienced TTNTD and TTD consistent with the median progression-free survival observed in its registrational trial, while patients treated with mobocertinib exhibited faster disease progression and a higher frequency of treatment discontinuation.
Authors
- Pratyusha Vadagam
- Jinghua He
- Dexter Waters (ORCID: https://orcid.org/0000-0002-9217-976X)
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Iris Lin
- Julie Vanderpoel (ORCID: https://orcid.org/0000-0001-5055-6216)
- Ran Tao (ORCID: https://orcid.org/0000-0002-9296-3992)
- Anjali Donnelly
Institutions
- Johnson & Johnson (United States) (US)
- Virginia Cancer Specialists (US)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100944
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Janssen Scientific Affairs